“EDAP” Ablatherm Integrated Imaging
HIFU minimally invasive therapy is suitable for patients with localized prostate cancer (T1-T2). The therapeutic effect can be equivalent to radical prostatectomy, and the incidence of postoperative complications is lower. During the treatment, the probe enters the patient’s rectum through the anus and destroys cancer cells with high-intensity focused ultrasound, which hardly affects surrounding organs and tissues. At the same time, the absence of wounds can greatly reduce the risk of infection and speed up the patient’s recovery time. In addition, for early-stage prostate cancer patients who cannot accept or unwilling to receive prostatectomy or other treatments, HIFU may be another treatment option. Patients with local recurrence can also receive HIFU as a salvage treatment.